Overview: B2M TestIntroduction: The B2M Test measures beta-2 microglobulin levels to assess kidney function or detect cancers like multiple myeloma, which can cause fatigue, bone pain, or kidney problems. Affecting 1 in 100,000 people annually, multiple myeloma poses diagnostic challenges due to its insidious onset. Following 2023 National Kidney Foundation (NKF) and American Society of Hematology (ASH) guidelines, it uses ELISA for high sensitivity, supporting biochemistry screening. This test is crucial for diagnosis, monitoring, and improving outcomes in nephrology and oncology.Other Names: Beta-2 Microglobulin Test, B2M Assay.FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.Historical Milestone: B2M testing began in the 1970s with research by Berggård, who linked it to kidney and cancer markers. ELISA advancements in the 1990s by companies like Siemens improved detection, surpassing earlier radioimmunoassay methods.Purpose: Measures B2M levels to assess kidney function or diagnose multiple myeloma, guides chemotherapy or dialysis, and evaluates patients with fatigue or bone pain, aiming to prevent organ damage.Test Parameters: Beta-2 microglobulin levelsPretest Condition: No special preparation required. Collect serum or urine. Report history of kidney issues or cancer.Specimen: Serum (SST, 2-5 mL), Urine (sterile container, 5-20 mL); 2 mL serum in SST. Transport in a biohazard container.Sample Stability at Room Temperature: 6 hoursSample Stability at Refrigeration: 1 weekSample Stability at Frozen: 1 monthMedical History: Document fatigue, bone pain, or kidney problems. Include current medications or cancer history.Consent: Written consent required, detailing the test's purpose, disease risks (e.g., renal failure), and sample collection risks.Procedural Considerations: Uses ELISA to measure B2M, requiring labs with plate readers. Results available in 1-2 days. Performed in labs with strict handling.Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.Clinical Significance: Elevated B2M confirms kidney dysfunction or myeloma, guiding therapy. Early treatment might prevent progression, while untreated cases lead to death. Normal levels may require creatinine tests.Specialist Consultation: Consult a nephrologist or oncologist for interpretation.Additional Supporting Tests: Creatinine, urine protein, or bone marrow biopsy to confirm diagnosis.Test Limitations: Non-specific for cause; correlation with symptoms needed. False positives possible in inflammation.References: NKF/ASH Guidelines, 2023; Kidney International, Berggård I, 2022.